Cargando…
Safety of Antiplatelet Agents: Analysis of ‘Real-World’ Data from the Italian National Pharmacovigilance Network
INTRODUCTION: According to the Italian National Report on drug use, thienopyridines (ticlopidine, clopidogrel and prasugrel) and ticagrelor represent the most prescribed antiplatelet agents, beside aspirin. The aim of this study was to analyse the safety profile of these drugs using data from sponta...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5643364/ https://www.ncbi.nlm.nih.gov/pubmed/28856572 http://dx.doi.org/10.1007/s40261-017-0566-4 |
_version_ | 1783271515608842240 |
---|---|
author | Gozzo, Lucia Navarria, Andrea Benfatto, Giuseppe Longo, Laura Mansueto, Silvana Sottosanti, Laura Pani, Luca Salomone, Salvatore Drago, Filippo |
author_facet | Gozzo, Lucia Navarria, Andrea Benfatto, Giuseppe Longo, Laura Mansueto, Silvana Sottosanti, Laura Pani, Luca Salomone, Salvatore Drago, Filippo |
author_sort | Gozzo, Lucia |
collection | PubMed |
description | INTRODUCTION: According to the Italian National Report on drug use, thienopyridines (ticlopidine, clopidogrel and prasugrel) and ticagrelor represent the most prescribed antiplatelet agents, beside aspirin. The aim of this study was to analyse the safety profile of these drugs using data from spontaneous reporting of suspected adverse reactions (ADRs). METHODS: Suspected ADRs for ticlopidine, clopidogrel, prasugrel and ticagrelor, reported on the Italian National Pharmacovigilance Network between January 2009 and December 2016, were included in the analysis. All suspected ADRs were classified by frequency, seriousness, outcome, age and system organ class. RESULTS: Clopidogrel showed the highest absolute number of suspected ADRs, followed by ticlopidine. However, these data need to be contextualized in view of the differences in marketing authorization dates, prescription rates and a characterization of the relative seriousness of ADRs per each drug. After the correction for prescription rate, ticagrelor showed the highest reporting trend and ticlopidine the lowest. Most ADRs occurred in the elderly, in particular for ticlopidine. Bleeding represents one of the most reported events (ticlopidine 40%, clopidogrel 26%, prasugrel 42%, ticagrelor 30%) and aspirin was the most frequently associated suspected drug. The majority of ADRs had complete recovery and were non-serious, except for ticlopidine (serious ADRs 53%). Prasugrel showed the highest percentage of ‘life-threatening’ events and ‘death’. CONCLUSIONS: Based on the analysis conducted on spontaneous ADRs reporting system in Italy, the safety profile of antiplatelet drugs seems favourable. However, the overall risk-benefit ratio of these drugs needs to be reassessed taking into account the appropriateness of use in particular populations at risk, such as the elderly. Based on this information, we believe that more attention from clinicians and/or an implementation of regulatory measures could be useful for clinical practice. |
format | Online Article Text |
id | pubmed-5643364 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Springer International Publishing |
record_format | MEDLINE/PubMed |
spelling | pubmed-56433642017-10-27 Safety of Antiplatelet Agents: Analysis of ‘Real-World’ Data from the Italian National Pharmacovigilance Network Gozzo, Lucia Navarria, Andrea Benfatto, Giuseppe Longo, Laura Mansueto, Silvana Sottosanti, Laura Pani, Luca Salomone, Salvatore Drago, Filippo Clin Drug Investig Original Research Article INTRODUCTION: According to the Italian National Report on drug use, thienopyridines (ticlopidine, clopidogrel and prasugrel) and ticagrelor represent the most prescribed antiplatelet agents, beside aspirin. The aim of this study was to analyse the safety profile of these drugs using data from spontaneous reporting of suspected adverse reactions (ADRs). METHODS: Suspected ADRs for ticlopidine, clopidogrel, prasugrel and ticagrelor, reported on the Italian National Pharmacovigilance Network between January 2009 and December 2016, were included in the analysis. All suspected ADRs were classified by frequency, seriousness, outcome, age and system organ class. RESULTS: Clopidogrel showed the highest absolute number of suspected ADRs, followed by ticlopidine. However, these data need to be contextualized in view of the differences in marketing authorization dates, prescription rates and a characterization of the relative seriousness of ADRs per each drug. After the correction for prescription rate, ticagrelor showed the highest reporting trend and ticlopidine the lowest. Most ADRs occurred in the elderly, in particular for ticlopidine. Bleeding represents one of the most reported events (ticlopidine 40%, clopidogrel 26%, prasugrel 42%, ticagrelor 30%) and aspirin was the most frequently associated suspected drug. The majority of ADRs had complete recovery and were non-serious, except for ticlopidine (serious ADRs 53%). Prasugrel showed the highest percentage of ‘life-threatening’ events and ‘death’. CONCLUSIONS: Based on the analysis conducted on spontaneous ADRs reporting system in Italy, the safety profile of antiplatelet drugs seems favourable. However, the overall risk-benefit ratio of these drugs needs to be reassessed taking into account the appropriateness of use in particular populations at risk, such as the elderly. Based on this information, we believe that more attention from clinicians and/or an implementation of regulatory measures could be useful for clinical practice. Springer International Publishing 2017-08-30 2017 /pmc/articles/PMC5643364/ /pubmed/28856572 http://dx.doi.org/10.1007/s40261-017-0566-4 Text en © The Author(s) 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. |
spellingShingle | Original Research Article Gozzo, Lucia Navarria, Andrea Benfatto, Giuseppe Longo, Laura Mansueto, Silvana Sottosanti, Laura Pani, Luca Salomone, Salvatore Drago, Filippo Safety of Antiplatelet Agents: Analysis of ‘Real-World’ Data from the Italian National Pharmacovigilance Network |
title | Safety of Antiplatelet Agents: Analysis of ‘Real-World’ Data from the Italian National Pharmacovigilance Network |
title_full | Safety of Antiplatelet Agents: Analysis of ‘Real-World’ Data from the Italian National Pharmacovigilance Network |
title_fullStr | Safety of Antiplatelet Agents: Analysis of ‘Real-World’ Data from the Italian National Pharmacovigilance Network |
title_full_unstemmed | Safety of Antiplatelet Agents: Analysis of ‘Real-World’ Data from the Italian National Pharmacovigilance Network |
title_short | Safety of Antiplatelet Agents: Analysis of ‘Real-World’ Data from the Italian National Pharmacovigilance Network |
title_sort | safety of antiplatelet agents: analysis of ‘real-world’ data from the italian national pharmacovigilance network |
topic | Original Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5643364/ https://www.ncbi.nlm.nih.gov/pubmed/28856572 http://dx.doi.org/10.1007/s40261-017-0566-4 |
work_keys_str_mv | AT gozzolucia safetyofantiplateletagentsanalysisofrealworlddatafromtheitaliannationalpharmacovigilancenetwork AT navarriaandrea safetyofantiplateletagentsanalysisofrealworlddatafromtheitaliannationalpharmacovigilancenetwork AT benfattogiuseppe safetyofantiplateletagentsanalysisofrealworlddatafromtheitaliannationalpharmacovigilancenetwork AT longolaura safetyofantiplateletagentsanalysisofrealworlddatafromtheitaliannationalpharmacovigilancenetwork AT mansuetosilvana safetyofantiplateletagentsanalysisofrealworlddatafromtheitaliannationalpharmacovigilancenetwork AT sottosantilaura safetyofantiplateletagentsanalysisofrealworlddatafromtheitaliannationalpharmacovigilancenetwork AT paniluca safetyofantiplateletagentsanalysisofrealworlddatafromtheitaliannationalpharmacovigilancenetwork AT salomonesalvatore safetyofantiplateletagentsanalysisofrealworlddatafromtheitaliannationalpharmacovigilancenetwork AT dragofilippo safetyofantiplateletagentsanalysisofrealworlddatafromtheitaliannationalpharmacovigilancenetwork |